Economic and Social Impact of Drug Policies · 8.5 Economic Benefits of Regulatory Policies

The criterion is not established.

Mexico has a legal framework permitting certain business activities related to medical cannabis, including research, production, manufacturing, import, export, and commercialization under sanitary regulation. There is also evidence of regulatory access by a multinational company and of a foreign acquisition involving a Mexican subsidiary.

However, the existence of an enabling legal framework, a corporate authorization, or a corporate transaction does not by itself establish foreign direct investment actually executed in a sector regulated by drug policy. No verifiable amount of foreign capital inflow, productive investment, installed assets, production capacity, jobs created, infrastructure developed, or commercial operation specifically attributable to medical cannabis, hemp, or another sector created or modified by drug-policy reform was identified.

The documented corporate authorization likewise does not establish this nexus. The evidence reviewed indicates that it concerns industrial cannabis, was obtained through judicial action, and was challenged by the regulatory authority; none of the identified sources quantifies investment executed as a result of that authorization.

Likewise, aggregate foreign investment recorded in Mexico's pharmaceutical industry cannot automatically be attributed to cannabis, hemp, controlled medicines, or other sectors directly linked to drug policy. A foreign acquisition involving a Mexican subsidiary also does not establish, without additional evidence on its object, capital, assets, and domestic execution, productive investment attributable to the sector under assessment.

Under the nexus criterion applied to economic indicators, enabling regulation, corporate presence, or aggregate sectoral investment is insufficient. There must be a verifiable link between foreign capital actually executed and the specific sector created, regulated, or transformed by drug policy.

Accordingly, executed, quantifiable, and attributable foreign direct investment in sectors specifically regulated by drug policy in Mexico is not established. The red classification reflects insufficient economic evidence directly linked to the object of the indicator and does not imply that no related foreign investment may exist. Factor X does not apply.